Drug Class: Angiogenesis and Growth Factor/ Receptor Inhibitors

Angiogenesis Inhibitors: Gas6 Antagonists

Platinum-Resistant/Refractory (Pt-R/Rf): Treatment given for recurrence occurring less than 6 months after last platinum-based treatment or for progression during last platinum-based treatment

Objective Response Rate (%)

Percentage of patients whose tumors shrink or go away after treatment

Progression Free Survival (months)

Median length of time before the cancer comes back or gets worse

1 Prior Therapy 2 Prior Therapies

Angiogenesis Inhibitors: Gas6 Antagonists

Platinum-Resistant/Refractory (Pt-R/Rf): Treatment given for recurrence occurring less than 6 months after last platinum-based treatment or for progression during last platinum-based treatment

For more detailed information, please click on the clinical trial ID number.

Trial ID # Phase Drugs Clinical Trial Title Key Conclusion and Results
Drugs in Clinical Development
NCT03639246 Ib/II Batiraxcept, Liposomal doxorubicin, Paclitaxel A Phase 1b/2 Randomized, Controlled Study of AVB-S6-500 in Combination With Pegylated Liposomal Doxorubicin (PLD) or Paclitaxel (Pac) in Patients With Platinum-resistant Recurrent Ovarian Cancer

AVB-S6-500+paclitaxel or liposomal doxorubicin is safe; the combination of AVB-S6-500+paclitaxel is most effective and best response is seen in patients without prior bevacizumab

AVB-S6-500+Pac vs AVB-S6-500+PLD:
ORR: 36.8 vs 16.0%
DCR: 68.4 vs 60.0%
PFS: 3.6 vs 3.6 months

AVB-S6-500+Pac; no prior Bev vs prior Bev:
ORR: 66.7 vs 10.0%
DCR: 88.9 vs 60%
PFS: 7.7 vs 2.8 months
OS: 19.3 vs 9.2 months

AVB-S6-500+Pac; trough levels above MEC vs below MEC:
ORR: 50 (n=10) vs 22% (n=9)
PFS: 7.5 vs 2.8 months

abs Jun 2021 and poster, pub 2021

< Return to Drug Classes

< Return to Clinical Trial Results Homepage